Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

被引：4

作者：

Salwender, Hans ^{[1
]}

Elmaagacli, Ahmet ^{[2
]}

Merz, Maximilian ^{[3
]}

Miah, Kaya ^{[4
]}

Benner, Axel ^{[4
]}

Haenel, Mathias ^{[5
]}

Jehn, Christian ^{[2
]}

Mai, Elias K. ^{[6
]}

Bertsch, Uta ^{[6
,7
]}

Blau, Igor W. ^{[8
]}

Scheid, Christof ^{[9
]}

Hose, Dirk ^{[10
]}

Seckinger, Anja ^{[10
]}

Jauch, Anna ^{[11
]}

Raab, Marc S. ^{[6
]}

Luntz, Steffen P. ^{[12
]}

Besemer, Britta ^{[13
]}

Munder, Markus ^{[14
]}

Brossart, Peter ^{[15
]}

Fuhrmann, Stephan ^{[16
]}

Lindemann, Hans-Walter ^{[17
]}

Weisel, Katja ^{[18
]}

Duerig, Jan ^{[19
]}

Goldschmidt, Hartmut ^{[6
,7
]}

机构：

[1] AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[2] Allgemein Krankenhaus St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[3] Univ Hosp Leipzig, Dept Hematol Celltherapy & Hemostaseol, Leipzig, Germany

[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[5] Klinikum Chemnitz, Chemnitz, Germany

[6] Univ Heidelberg Hosp, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[8] Charite, Berlin, Germany

[9] Univ Hosp Cologne, Cologne, Germany

[10] Vrije Univ Brussel VUB, Lab Hematol & Immunol & Labor Myelomforsch, Jette, Belgium

[11] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[12] Coordinat Ctr Clin Trials KKS, Heidelberg, Germany

[13] Univ Tubingen Hosp, Tubingen, Germany

[14] Univ Med Ctr Mainz, Mainz, Germany

[15] Univ Hosp Bonn, Bonn, Germany

[16] Helios Hosp Berlin Buch, Buch, Germany

[17] Kath Krankenhaus Hagen, Hagen, Germany

[18] Univ Hamburg Hosp, Hamburg, Germany

[19] Univ Hosp Essen, Essen, Germany

来源：

LEUKEMIA | 2021年 / 35卷 / 10期

关键词：

PERIPHERAL NEUROPATHY; DEXAMETHASONE; LENALIDOMIDE;

D O I：

10.1038/s41375-021-01298-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3007 / 3011

页数：5

共 50 条

[31] Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Kumar, Shaji K.
Berdeja, Jesus G.
Niesvizky, Ruben
Lonial, Sagar
Laubach, Jacob P.
Hamadani, Mehdi
Stewart, A. Keith
Hari, Parameswaran
Roy, Vivek
Vescio, Robert
Kaufman, Jonathan L.
Berg, Deborah
Liao, Eileen
Rajkumar, S. Vincent
Richardson, Paul G.
LEUKEMIA, 2019, 33 (07) : 1736 - 1746
[32] Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution
Franssen, Laurens E.
Raymakers, Reinier A. P.
Buijs, Arjan
Schmitz, Marian F.
van Dorp, Suzanne
Mutis, Tuna
Lokhorst, Henk M.
van de Donk, Niels W. C. J.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (05) : 479 - 488
[33] Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Shaji K. Kumar
Jesus G. Berdeja
Ruben Niesvizky
Sagar Lonial
Jacob P. Laubach
Mehdi Hamadani
A. Keith Stewart
Parameswaran Hari
Vivek Roy
Robert Vescio
Jonathan L. Kaufman
Deborah Berg
Eileen Liao
S. Vincent Rajkumar
Paul G. Richardson
Leukemia, 2019, 33 : 1736 - 1746
[34] Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study
Rosinol, Laura
Oriol, Albert
Isabel Teruel, Ana
Hernandez, Dolores
Jesus Blanchard, M.
De La Rubia, Javier
Granell, Miquel
Besalduch, Juan
Palomera, Luis
Gonzalez, Yolanda
Asuncion Echebeste, M.
Diaz-Mediavilla, Joaqun
Hernandez, Miguel T.
de Arriba, Felipe
Carmen Gutierrez, Norma
Luisa Martin-Ramos, M.
Teresa Cibeira, M.
Victoria Mateos, Maria
Martinez-Lopez, Joaquin
Alegre, Adrian
Lahuerta, Juan Jose
San Miguel, Jesus F.
Blade, Joan
BLOOD, 2014, 124 (21)
[35] Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial
Jackson, Graham
Pawlyn, Charlotte
Cairns, David
Jones, John R.
Kishore, Bhuvan
Garg, Mamta
Williams, Cathy
Karunanithi, Kamaraj
Lindsay, Jindriska
Russell, Nigel H.
Jenner, Matthew
Cook, Gordon
Drayson, Mark T.
Owen, Roger G.
Gregory, Walter M.
Kaiser, Martin F.
Davies, Faith E.
Morgan, Gareth
BLOOD, 2019, 134
[36] Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Moreau, Philippe
Hulin, Cyrille
Perrot, Aurore
Arnulf, Bertrand
Belhadj, Karim
Benboubker, Lotfi
Zweegman, Sonja
Caillon, Helene
Caillot, Denis
Avet-Loiseau, Herve
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Sonntag, Cecile
Fontan, Jean
Mohty, Mohamad
Jie, Kon-Siong
Karlin, Lionel
Kuhnowski, Frederique
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Orsini-Piocelle, Frederique
Roussel, Murielle
Colella, Jean Marc Schiano de
van de Donk, Niels W. C. J.
Wuilleme, Soraya
Broijl, Annemiek
Touzeau, Cyrille
Tiab, Mourad
Marolleau, Jean-Pierre
Meuleman, Nathalie
Vekemans, Marie-Christiane
Westerman, Matthijs
Klein, Saskia K.
Levin, Mark-David
Offner, Fritz
Escoffre-Barbe, Martine
Eveillard, Jean-Richard
Garidi, Reda
Hua, Winnie
Wang, Jianping
Tuozzo, Alba
de Boer, Carla
Rowe, Melissa
Vanquickelberghe, Veronique
Carson, Robin
Vermeulen, Jessica
Corre, Jill
Sonneveld, Pieter
LANCET ONCOLOGY, 2024, 25 (08): : 1003 - 1014
[37] Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial
Scheid, Christof
Seckinger, Anja
Durig, Jan
Weisel, Katja C.
Kunz, Christina
Bertsch, Uta
Hielscher, Thomas
Munder, Markus
Lindemann, Hans-Walter
Huegle-Doerr, Barbara
Huhn, Stefanie
Mai, Elias K.
Jauch, Anna
Rabold, Bernhard
Gerecke, Christian
Brossart, Peter
Goerner, Martin
Bernhard, Helga
Hoffmann, Martin
Hillengass, Jens
Raab, Marc-Steffen S.
Blau, Igor Wolfgang
Haenel, Mathias
Hose, Dirk
Goldschmidt, Hartmut
Salwender, Hans Jurgen
BLOOD, 2017, 130
[38] Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Al Hadidi, Samer
Ababneh, Obada
Schinke, Carolina
Thanendrarajan, Sharmilan
Bailey, Clyde
Smith, Robert
Panozzo, Susan
Alapat, Daisy
Tricot, Guido
Shaughnessy Jr, John
Zhan, Fenghuang
Sawyer, Jeffrey
Siegel, Eric R.
Barlogie, Bart
Van, Frits
Zangari, Maurizio
BLOOD ADVANCES, 2025, 9 (04) : 950 - 953
[39] Whole-Body Reduced-Dose CT As Primary Staging and during Follow-up in First-Line Treatment of TransplantEligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial
Weisel, Katja
Horger, Marius
Goldschmidt, Hartmut
Kanz, Lothar
Delorme, Stefan
Hillengass, Jens
BLOOD, 2014, 124 (21)
[40] Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study
Blanes, Margarita
Ignacio Lorenzo, Jose
Ribas, Paz
Jimenez, Ana
David Gonzalez, Jose
Jose Cejalvo, Maria
Solano, Carlos
Alegre, Adrian
de la Rubia, Javier
BONE MARROW TRANSPLANTATION, 2019, 54 : 214 - 215

← 1 2 3 4 5 →